Jordan L Schultz1,2,3, John A Kamholz1,2, Peg C Nopoulos1,2,4, Annie Killoran2,5. 1. Department of Psychiatry The University of Iowa Hospitals and Clinics Iowa City IA United States. 2. Department of Neurology The University of Iowa Hospitals and Clinics Iowa City IA United States. 3. Department of Pharmaceutical Care The University of Iowa Hospitals and Clinics Iowa City IA United States. 4. Stead Family Department of Pediatrics The University of Iowa Hospitals and Clinics Iowa City IA United States. 5. The Veteran's Affairs Medical Center Iowa City IA United States.
Abstract
INTRODUCTION: Huntington's chorea (HC) is commonly managed with neuroleptic medications, though there is little evidence to support their use. This study aimed to perform a real-world comparison of the efficacy of risperidone and olanzapine to tetrabenazine (TBZ) for HC. METHODS: The Enroll-HD database was used to perform a propensity score-matched comparison of risperidone and olanzapine to TBZ, regarding their efficacy in controlling chorea. Participants with motor manifest Huntington's disease (HD) were grouped according to their use of risperidone, olanzapine, or TBZ. For the three groups, independent propensity score matching was performed on participants' baseline total functional score (TFC), baseline total motor score (TMS), disease burden score, CAG repeat length, baseline age, region, sex, and body mass index. Independent samples t test was used to calculate the differences between the groups in the annual rate of change of the TMS from the baseline to the second available visit. RESULTS: The risperidone (n = 72) and olanzapine groups (n = 77) had annualized increases (worsening) in the TMS of only 1.47 points and 3.20 points, respectively, compared to 5.70 points in the two matched TBZ groups (n = 72) (P = 0.019) and (n = 77) (P = 0.143), respectively. CONCLUSIONS: In the absence of prospective data, this analysis of the Enroll-HD database found that the neuroleptics risperidone and olanzapine seemed to at least be comparable to TBZ at controlling HC. These results demonstrate that neuroleptics may have comparable efficacy to TBZ for the treatment of HC. Further prospective studies are needed to confirm these findings.
INTRODUCTION: Huntington's chorea (HC) is commonly managed with neuroleptic medications, though there is little evidence to support their use. This study aimed to perform a real-world comparison of the efficacy of risperidone and olanzapine to tetrabenazine (TBZ) for HC. METHODS: The Enroll-HD database was used to perform a propensity score-matched comparison of risperidone and olanzapine to TBZ, regarding their efficacy in controlling chorea. Participants with motor manifest Huntington's disease (HD) were grouped according to their use of risperidone, olanzapine, or TBZ. For the three groups, independent propensity score matching was performed on participants' baseline total functional score (TFC), baseline total motor score (TMS), disease burden score, CAG repeat length, baseline age, region, sex, and body mass index. Independent samples t test was used to calculate the differences between the groups in the annual rate of change of the TMS from the baseline to the second available visit. RESULTS: The risperidone (n = 72) and olanzapine groups (n = 77) had annualized increases (worsening) in the TMS of only 1.47 points and 3.20 points, respectively, compared to 5.70 points in the two matched TBZ groups (n = 72) (P = 0.019) and (n = 77) (P = 0.143), respectively. CONCLUSIONS: In the absence of prospective data, this analysis of the Enroll-HD database found that the neuroleptics risperidone and olanzapine seemed to at least be comparable to TBZ at controlling HC. These results demonstrate that neuroleptics may have comparable efficacy to TBZ for the treatment of HC. Further prospective studies are needed to confirm these findings.
Authors: Jordan L Schultz; Annie Killoran; Peg C Nopoulos; Chloe C Chabal; David J Moser; John A Kamholz Journal: Neurology Date: 2018-06-20 Impact factor: 9.910
Authors: Samuel Frank; Claudia M Testa; David Stamler; Elise Kayson; Charles Davis; Mary C Edmondson; Shari Kinel; Blair Leavitt; David Oakes; Christine O'Neill; Christina Vaughan; Jody Goldstein; Margaret Herzog; Victoria Snively; Jacquelyn Whaley; Cynthia Wong; Greg Suter; Joseph Jankovic; Joohi Jimenez-Shahed; Christine Hunter; Daniel O Claassen; Olivia C Roman; Victor Sung; Jenna Smith; Sarah Janicki; Ronda Clouse; Marie Saint-Hilaire; Anna Hohler; Denyse Turpin; Raymond C James; Ramon Rodriguez; Kyle Rizer; Karen E Anderson; Hope Heller; Alexis Carlson; Susan Criswell; Brad A Racette; Fredy J Revilla; Frederick Nucifora; Russell L Margolis; MaryJane Ong; Tilak Mendis; Neila Mendis; Carlos Singer; Monica Quesada; Jane S Paulsen; Thomas Brashers-Krug; Amanda Miller; Jane Kerr; Richard M Dubinsky; Carolyn Gray; Stewart A Factor; Elaine Sperin; Eric Molho; Mary Eglow; Sharon Evans; Rajeev Kumar; Christina Reeves; Ali Samii; Sylvain Chouinard; Monica Beland; Burton L Scott; Patrick T Hickey; Sherali Esmail; Wai Lun Alan Fung; Clare Gibbons; Lina Qi; Amy Colcher; Cory Hackmyer; Andrew McGarry; Kevin Klos; Mark Gudesblatt; Lori Fafard; Laura Graffitti; Daniel P Schneider; Rohit Dhall; Joanne M Wojcieszek; Kathrin LaFaver; Andrew Duker; Erin Neefus; Hilary Wilson-Perez; David Shprecher; Paola Wall; Karen A Blindauer; Lynn Wheeler; James T Boyd; Emily Houston; Eric S Farbman; Pinky Agarwal; Shirley W Eberly; Arthur Watts; Pierre N Tariot; Andrew Feigin; Scott Evans; Chris Beck; Constance Orme; Jon Edicola; Emily Christopher Journal: JAMA Date: 2016-07-05 Impact factor: 56.272
Authors: Anna A M Hubers; Erik van Duijn; Raymund A C Roos; David Craufurd; Hugh Rickards; G Bernhard Landwehrmeyer; Rose C van der Mast; Erik J Giltay Journal: J Affect Disord Date: 2013-07-20 Impact factor: 4.839
Authors: Pubu M Abeyasinghe; Jeffrey D Long; Adeel Razi; Dorian Pustina; Jane S Paulsen; Sarah J Tabrizi; Govinda R Poudel; Nellie Georgiou-Karistianis Journal: Mov Disord Date: 2021-05-20 Impact factor: 9.698